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Abstract
Introduction: Fibronectin is one of the most abundant proteins present in the inflamed joint. Here, we
characterized the citrullination of fibronectin in the joints of rheumatoid arthritis (RA) patients and studied the
prevalence, epitope specificity and human leukocyte antigen (HLA) association of autoantibodies against
citrullinated fibronectin in RA.
Methods: Citrullinated residues in fibronectin isolated from RA patient synovial fluid were identified by mass
spectrometry. The corresponding citrullinated and non-citrullinated peptides were synthesized and used to analyze
the presence of autoantibodies to these peptides in RA sera and sera from other diseases and healthy controls by
ELISA. The data were compared with risk factors like shared epitope HLA alleles and smoking, and with clinical
features.
Results: Five citrullinated residues were identified in fibronectin from RA synovial fluid. RA sera reacted in a
citrulline-dependent manner with two out of four citrullinated fibronectin peptides, one of which contains two
adjacent citrulline residues, in contrast to non-RA sera, which were not reactive. The most frequently recognized
peptide (FN-Cit1035,1036, LTVGLTXXGQPRQY, in which × represents citrulline) was primarily targeted by anti-CCP
(cyclic citrullinated peptide) 2-positive RA patients. Anti-FN-Cit1035,1036 autoantibodies were detected in 50% of
established anti-CCP2-positive RA patients and in 45% of such patients from a early arthritis clinic. These antibodies
appeared to be predominantly of the immunoglobulin G (IgG) isotype and to be associated with HLA shared
epitope alleles (odds ratio = 2.11).
Conclusions: Fibronectin in the inflamed synovia of RA patients can be citrullinated at least at five positions.
Together with the flanking amino acids, three of these citrullinated residues comprise two epitopes recognized by
RA autoantibodies. Anti-citrullinated fibronectin peptide antibodies are associated with HLA shared epitope alleles.
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Introduction
Citrullination or deimination is a post-translational
modification, in which a peptidylarginine is converted
into a peptidylcitrulline by the enzyme family of pepti-
dylarginine deiminases (PAD). Citrullinated proteins
occur at inflamed sites in healthy individuals as well as
in patients [1,2]. However, autoantibodies directed
against citrullinated proteins (anti-citrullinated protein/
peptide antibodies, ACPA) are very specific for rheuma-
toid arthritis (RA). More than 70% of RA patients dis-
play ACPA, measured via the anti-CCP2 (cyclic
citrullinated peptide 2) test, in their sera [3,4]. These
antibodies are frequently present prior to disease onset
and can predict the development of RA [5,6].
It is still not fully understood how RA originates and
develops, although there is experimental evidence for
several steps in this process [7]. Both genetic and
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environmental factors have been demonstrated to con-
tribute to the development of the disease and ACPA
production. The association of several HLA-DRB1
alleles, which all share a highly conserved motif that is
known as the shared epitope (SE), has already been
reported many years ago [8,9]. Other genes that have
been identified as risk factors for RA include PTPN22,
the TRAF1-C5 locus, PADI4, STAT4, IRF5 and CTLA-4
[10-15]. Smoking has been demonstrated to be an envir-
onmental risk factor for RA and also for ACPA produc-
tion in RA patients carrying SE alleles [16,17]. Other
environmental risk factors that have been suggested to
enhance the chance of developing RA include the expo-
sure to mineral oil, diet restrictions and coffee intake
[18-20]. However, these data still need confirmation.
Many citrullinated autoantigens (for example, fibrino-
gen, vimentin, a-enolase) and ACPA directed towards
these citrullinated proteins have been identified in RA
[21-26]. Currently, the CCP2 test, which is based on a
synthetic citrullinated peptide not related to proteins
occurring in the inflamed joints of RA patients, is the
gold standard [27-29] for ACPA testing. ACPA have
recently been included in the new American College of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) criteria for the classification of RA,
because they are present early in the disease and can
predict disease development and outcome [5,30]. The
ACPA response in established RA patients is very het-
erogeneous and includes antibodies directed to many
citrullinated proteins [31-33]. Because it has been sug-
gested that ACPA play an important role in the devel-
opment of the disease, it is important to learn more
about the autoantigens that could be involved in the
generation of ACPA [7]. Several citrullinated proteins
occurring in the inflamed joints of RA patients have
been identified previously. In part, their citrulline-con-
taining epitopes have been mapped, particularly using
synthetic peptides [24,34] or material from cultured
(non-synovial) cells (for example, HL-60 cells) [23]. It
remains to be established whether these epitopes are
relevant from a pathophysiological point of view. ACPA
tests based upon citrullinated autoantigenic proteins
may provide information on ACPA fine-specificities
[35,36] and may aid the differentiation between clinically
distinct RA patient subgroups, although so far no corre-
lations between ACPA fine-specificities and clinical phe-
notypes have been found [37-39].
One of the citrullinated proteins in inflamed synovial
tissue identified previously is fibronectin (FN) [40,41].
FN is a glycoprotein, which can be a component of the
extracellular matrix (insoluble form) or present in body
fluids (soluble form). FN is involved in a variety of pro-
cesses, such as wound healing, haemostasis, thrombosis
and embryogenesis [42]. Several findings have been
published linking (citrullinated) FN with RA. For exam-
ple, citrullinated FN was found to be present in synovial
tissue and synovial fluid (SF) of RA patients [41,43]. It
has also been detected in pannus tissue and in immune
complexes present in sera of RA patients [44,45]. FN
might play a role in articular cartilage destruction,
because it has been observed that FN fragments can sti-
mulate the production of multiple mediators of matrix
destruction, such as various cytokines and metalloprotei-
nases [46,47]. However, the presence and characteristics
of anti-citrullinated fibronectin antibodies in RA patients
have not been studied yet.
In the current study, we have mapped citrullinated
residues of FN isolated from the SF of RA patients and
have used this information to investigate the B-cell
response to citrullinated FN in RA.
Materials and methods
Patient material
Synovial fluid (SF) samples from RA patients were a
kind gift from Prof. Dr. B. Bozic (Department of Rheu-
matology, University Medical Center, Ljubljana, Slove-
nia). After SF samples were obtained by joint punctures
(arthrocentesis), using needles with a diameter from 1.6
to 2.2 mm, they were immediately centrifuged at 2,500
× g for 10 minutes at 4°C to separate insoluble and
soluble components into pellet and supernatant frac-
tions, respectively. Supernatant and pellet fractions were
separately stored at -80°C within two hours after taking
the samples. The pellets were resuspended in EGTA
lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM KCl, 1
mM DTE, 0.1% NP40, 10 mM EGTA, 0.5 mM PMSF
and protease inhibitor cocktail). Supernatant fractions
were diluted in five volumes of EGTA lysis buffer. After
sonification, SDS was added (final concentration 2%)
and the fractions were heated and centrifuged at 12,000
× g. Supernatants were used for further analysis.
Sera from (established) rheumatoid arthritis (RA; n =
110), systemic lupus erythematosus (SLE; n = 31), and
primary Sjőgren’s syndrome (pSS; n = 31) patients were
collected at the Department of Rheumatology of the
University Medical Centre Nijmegen and the St. Maar-
tenskliniek Nijmegen (The Netherlands). Sera from mul-
tiple sclerosis (MS; n = 31) patients were collected at
the MS Centrum Nijmegen (The Netherlands). Type 1
diabetes (T1D; n = 32) sera were obtained from the
Department of Immunohaematology and Blood Transfu-
sion of the Leiden University Medical Centre (Leiden,
The Netherlands). Early arthritis sera (EAC; n = 301)
were collected at the Department of Rheumatology of
the Leiden University Medical Center (Leiden, The
Netherlands) [48]. Tuberculosis (TB; n = 29) sera were
collected at Department of Internal Medicine, Tel Aviv
Medical Center, Israel. Sera from healthy individuals
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(NS; n = 32) were collected at the Sanquin Blood Bank
in Nijmegen. Sera were stored at -70°C until use.
ACPA levels in RA sera were measured using a com-
mercial CCP2 ELISA kit (Euro-Diagnostica A.B.,
Malmo, Sweden).
These studies were approved by the local ethics com-
mittees; the need for patient consent was waived by the
local ethics committees.
Sample preparation and tandem mass spectrometry
analysis
Two SF samples from RA patients, the supernatant frac-
tion of one and the pellet of the other, were depleted of
albumin as described by Colantonio and coworkers [49],
separated by SDS-PAGE and stained with colloidal Coo-
massie Brilliant Blue. Each lane of the gel, containing
material from an individual SF sample, was sliced into 18
pieces and the polypeptides in these gel slices were
digested after the addition of 20 μL trypsin solution (15
ng/μL trypsin in 25 mM NH4HCO3 and 5 mM n-octyl-
pyranoglucoside). Peptides were extracted by adding 50%
acetonitril, 0.5% trifluoroacetic acid, 5 mM n-octylpyra-
noglucoside followed by sonication. The protein digests
resulting from each of the gel slices were separately ana-
lyzed by nano-LC-MS/MS (using a LTQ (linear trap
quadrupole) Fourier Transform Ion Cyclotron Resonance
mass spectrometer (LTQ FT, Thermo Scientific, Wal-
tham, MA, USA)). Data were converted by BioWorks
SEQUEST (Thermo Electron, Waltham, MA, USA) into
a peak list, which allowed peptide identification with the
Mascot Search database. Additionally, citrullination sites
were checked manually. Mass deviations for precursor
ions were set to 20 ppm and deviations for the mass of
fragment ions were set at 0.8 Da. Fixed modifications,
besides citrullination, such as oxidation and methylation,
were taken along during the analysis.
Synthesis of citrullinated fibronectin peptides
Peptides (Table 1) were synthesized by a solid-phase
procedure using Fmoc chemistry as described previously
[50]. The peptides were at least 90% pure as deduced
from their elution pattern on reversed phase HPLC.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assays (ELISA) with
fibronectin peptides were performed as described pre-
viously. Briefly, each well of a microtiter plate (Strepta-
well, Roche, Basel, Switzerland) was coated with 1 μg
biotinylated peptide in 0.1 mL PBS/0.1% BSA overnight
at 4°C. After washing three times with PBST0.1 (PBS,
0.1% Tween20), wells were incubated with serum sam-
ples 100-fold diluted at in PBST0.05 (PBS, 0.05%
Tween20) containing 1% BSA for one hour at 37°C.
After incubation, plates were washed three times with
PBST0.1, followed by an incubation at 37°C with HRP-
conjugated goat anti-human IgG, IgM, IgA, kappa,
lambda (DAKO, Glostrup, Denmark) or with either
HRP-conjugated rabbit anti-human IgG, rabbit anti-
human IgM or rabbit anti-human IgA (DAKO,
Glostrup, Denmark). Bound antibodies were detected by
the conversion of 3,3’,5,5’-tetramethylbenzidine (TMB)
and, after terminating the reaction by the addition of
sulfuric acid, the absorbance was measured at 450 nm.
Cut-off values were determined as the mean value plus
two times the standard deviation of normal human con-
trol sera.
ACPA fine specificity ELISA assays using peptides
derived from citrullinated vimentin, fibrinogen and a-
enolase were performed as described previously [39,51].
Statistics
A two-tailed unpaired t-test with a CI of 95% was used
to observe differences in reactivity between RA sera and
non-RA sera with respect to the citrullinated peptides.
Univariate logistic regression analyses were performed
for testing the association between several single risk
factors (SE alleles as well as smoking) and anti-citrulli-
nated fibronectin peptide antibodies in early arthritis
patients. A Mann-Whitney U test was performed to
address associations with the clinical phenotype (HAQ
Table 1 Sequences of synthetic fibronectin peptides
Peptide
name
Peptides identified in RA SFa Synthetic peptidea Citrulline residues identified in
RA1
Citrulline residues identified in
RA2
FN-Cit241 DTRTSYXIGDTWSK, TSYXIGDTWSK DTRTSYXIGDTWSZO X X
FN-Arg241 DTRTSYRIGDTWSZO
FN-Cit1035,1036 LTVGLTXXGQPR,
AQITGYRLTVGLTXR
LTVGLTXXGQPRQYZO X Xb
FN-Arg1035,1036 LTVGLTRRGQPRQYZO
FN-Cit1162 DGQEXDAPIVNK LRDGQEXDAPIVNZO X X
FN-Arg1162 LRDGQERDAPIVNZO
FN-Cit2356 RPGGEPSPEGTTGQSYNQYSQXYHQR YNQYSQXYHQRTNZO X
FN-Arg2356 YNQYSQRYHQRTNZO
a O, biotinylated lysine; X, citrulline; Z, aminohexanoic acid. b Only citrulline at position 1035 was identified
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(health assessment questionnaire) score, VAS (visual
analog scale) score, swollen joint count and Ritchie
index) of the early arthritis patients.
Results
Citrullinated fibronectin in synovial fluid samples of RA
patients
To study the immune response to citrullinated FN in
RA, first the positions of the citrulline residues in FN
isolated from the inflamed joints of RA patients were
mapped. One supernatant fraction and one pellet frac-
tion from SF samples obtained from two different RA
patients (RA1 and RA2, respectively) were depleted of
albumin by a differential precipitation procedure as
described previously [49]. This resulted in two pellet
fractions for each RA SF sample, which were separated
by SDS-PAGE and stained with colloidal Coomassie
Brilliant Blue (CBB) (Additional file 1: Figure S1). Subse-
quently, 18 equal slices, covering the largest
polypeptides (slice number 1, molecular weight >
94,000) to the smallest polypeptides (slice number 18,
molecular weight < 14,000) were excised from the
stained gel for both samples (Figure 1A). The polypep-
tides present in the slices were digested with trypsin and
analyzed by LC-MS/MS. The identity of polypeptides
and the positions of citrullinated residues were deter-
mined by database searches using Mascot (Version
2.1.03, Matrix Science Inc, Boston, MA, USA). To con-
firm the presence of citrullinated residues and to distin-
guish from deamidation of glutamine or asparagine
residues, the peptide fragmentation patterns were
inspected manually. One of the citrullinated proteins
found in the SF of both patients was FN.
Figure 1B shows a schematic overview of all the FN
peptide sequences obtained. This indicates that (frag-
ments of) FN were present in material from many gel
slices, indicative of a large variety of FN polypeptide
lengths in SF samples. FN is a protein for which at least
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Figure 1 Identification of (citrullinated) FN in RA synovial fluid. A. RA synovial fluid samples were depleted of albumin and separated by
SDS-PAGE and stained with colloidal Coomassie Brilliant Blue. Subsequently, 18 equal slices were excised from the stained gel for both samples.
The polypeptides present in the slices were digested with trypsin and analyzed by LC-MS/MS. The presence of citrullinated proteins in the gel
was visualized by Western blotting using anti-modified citrulline (AMC) antibodies after modification of the proteins on the blot. The positions of
molecular mass markers are indicated on the left (kDa). B. The positions of FN peptides detected in RA SF with LC-MS/MS for each of the 18 gel
slices of both patient samples are schematically aligned with isoform 1 of fibronectin (FN1). The white bars represent peptides detected in RA1,
the black bars peptides detected in RA2 and the grey bars peptides detected in both patients. The positions of the citrullinated residues
detected are marked with asterisks. C. Schematic overview of the 15 different FN isoforms, resulting from alternative splicing events,
documented in the UniProtKB database. The positions of the main alternatively spliced segments EDA, EDB and IIICS are indicated.
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15 different isoforms exist (Figure 1C); the canonical iso-
form (FN1) comprises a polypeptide of 2,386 amino
acids, in which three repeats can be discerned [52]. FN-
derived peptides that were found by these analyses cov-
ered most of the FN1 isoform, although for several
regions no peptides were detected, which may at least in
part be due to poor ionization efficiencies. For one of the
alternatively spliced segments, extra domain A (EDA), no
peptides were found in the data obtained, whereas several
peptides demonstrating the absence of EDA were pre-
sent. For IIICS, another alternatively spliced region, some
peptide sequences were obtained with material from the
high molecular weight fractions. Altogether, the mass
spectrometry data covered 53% and 28% of the FN iso-
form 1 sequence for RA1 and RA2, respectively (Figure
1B and Additional file 1: Figure S2).
A search for deiminated arginines identified four
citrullinated FN regions containing five citrullinated
residues, located at amino acid positions 241, 1035,
1036, 1162 and 2356 (Figure 1B). In RA1, four citrulli-
nated residues were identified (positions 241, 1035, 1036
and 1162), whereas in the second patient (RA2) four
citrullinated residues were identified (positions 241,
1035, 1162 and 2356) (Figure 1A and Table 1).
Anti-citrullinated fibronectin peptide antibodies are
specific for RA and are associated with the ACPA
response
To investigate the antigenicity of citrullinated FN, pep-
tides comprising the citrullination sites identified were
synthesized, as well as their arginine-containing counter-
parts (Table 1). A single peptide was synthesized for the
flanking citrullination sites at positions 1035 and 1036,
similar to the peptide identified in RA SF. The recogni-
tion of these peptides by antibodies in established RA
patient sera (n = 23) was analyzed by ELISA. Two of
these peptides, which contained either a citrulline at
position 241 or at position 1162 (FN-Cit241 and FN-
Cit1162, respectively), were not recognized by RA sera. In
contrast, the other two peptides (FN-Cit1035,1036 and
FN-Cit2356) were reactive with RA sera, and for both
this reactivity appeared to be citrulline-dependent (Fig-
ure 2A-D). To substantiate these data and to obtain an
indication of the frequency by which these peptides are
recognized, sera from a second, larger cohort of 80
established RA patients were analyzed. Also these sera
were found to be frequently reactive with the FN-
Cit1035,1036 and FN-Cit2356 peptides (Figure 2E, F).
Forty-three percent of these sera appeared to recognize
FN-Cit1035,1036, whereas eight percent was reactive with
FN-Cit2356. To analyze the disease-specificity of antibo-
dies to these citrullinated FN peptides, sera from 31
multiple sclerosis (MS), 32 type 1 diabetes (T1D), 31
primary Sjőgren’s syndrome (pSS), 31 systemic lupus
erythematosus (SLE) and 29 tuberculosis (TB) patients,
and from 32 healthy individuals, in parallel with 75
established RA sera, were analyzed by ELISA. The
results showed that less than two percent of the control
sera was reactive with FN-Cit1035,1036, whereas one per-
cent displayed reactivity with FN-Cit2356 (Figure 3).
Recently, it was shown that RA patients can be
divided into two subsets based upon the presence or
absence of ACPA in their sera and the CCP2 test
appeared to be very suitable to differentiate between
these subsets [53]. The analysis of anti FN-Cit1035,1036
reactivity in 131 anti-CCP2-positive and 28 anti-CCP2-
negative RA sera (Figure 4) showed that the anti-citrulli-
nated fibronectin antibodies were hardly present in anti-
CCP2-negative RA sera, corroborating the idea that
these antibodies are part of the ACPA response in anti-
CCP2-positive RA patients. The combined analyses of
the established RA sera resulted in a prevalence of 50
percent for the autoantibodies to peptide FN-Cit1035,1036
(Table 2), LTVGLTXXGQPRQY (X represents citrul-
line), in CCP2-positive established RA sera (n = 82).
Autoantibodies against citrullinated fibronectin peptide
are present early in the disease
Autoantibodies against CCP2 peptides have been demon-
strated to be detectable very early in the disease. Moreover,
their presence in pre-disease sera predicts the development
of RA [5,6,54]. The diversification of the ACPA response
was found to occur mainly in the pre-disease stage. To
investigate whether autoantibodies against citrullinated FN
are also detectable in the early stages of RA development, a
number of sera from early arthritis (EAC) patients (CCP2-
negative, n = 23; CCP2-positive, n = 24) was analyzed. As
observed before for the established RA sera, also the EAC
sera reactive with the FN-Cit1035,1036 peptide represented a
subgroup of the anti-CCP2-positive patients (Figure 5A).
To substantiate these data and to obtain an indication of
the frequency by which the FN-Cit1035,1036 peptide was
recognized, additional CCP2-positive early arthritis sera (n
= 278) were analyzed. Forty-five percent of these CCP2-
positive EAC sera appeared to be reactive with the citrulli-
nated fibronectin peptide containing citrulline residues at
positions 1035 and 1036 (Figure 5B and Table 2). Only a
small fraction of these early arthritis sera (4%) displayed
some reactivity with the corresponding arginine-containing
peptide (Figure 5B).
It is known that after disease onset ACPA isotype
switching may occur [55]. To investigate isotype switching
of antibodies to citrullinated FN, 23 anti-FN-Cit1035,1036-
positive sera for which both samples taken at baseline and
approximately seven years after disease onset were avail-
able, were selected and analyzed in ELISA with isotype-
specific (IgG, IgM and IgA) secondary antibody conju-
gates. At baseline (t = 0), 87% of the reactive sera
van Beers et al. Arthritis Research & Therapy 2012, 14:R35
http://arthritis-research.com/content/14/1/R35
Page 5 of 16
Figure 2 Recognition of citrullinated fibronectin peptides by RA sera. The four fibronectin peptide sets (A, FN-Arg/Cit241; B, FN-Arg/
Cit1035,1036; C, FN-Arg/Cit1162; D, FN-Arg/Cit2356) were analyzed by ELISA with 23 sera from established RA patients. Two peptide sets (E, FN-Arg/
Cit1035,1036; F, FN-Arg/Cit2356) were analyzed with a larger cohort obtained from established RA sera (n = 80). OD450 = optical density at 450 nm.
van Beers et al. Arthritis Research & Therapy 2012, 14:R35
http://arthritis-research.com/content/14/1/R35
Page 6 of 16
contained immunoglobulins of the IgG isotype (Figure
6A), whereas 13% contained IgM (Figure 6C) and 4% con-
tained IgA (Figure 6E) type reactivities. After a median fol-
low-up time of seven years (t = 7) the frequency of IgG
type antibodies to FN-Cit1035,1036 was slightly decreased to
74% (Figure 6B). In these patients the frequency of IgM
type anti-FN-Cit1035,1036 antibodies decreased to 4% (Fig-
ure 6D) In contrast, at this stage the frequency of IgA type
antibodies to this citrullinated FN peptide increased to
13% (Figure 6F). All IgM- and IgA-positive patients were
also positive for IgG, whereas the simultaneous presence
of IgM and IgA reactivities in the same patients was
observed in one patient. Except for two patients, in which
the IgG type anti-FN-Cit1035,1036 antibodies disappeared,
the presence of these IgG antibodies did not markedly
change in time (Figure 6G).
Anti-citrullinated fibronectin peptide antibodies are
associated with HLA SE alleles
The HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*10 and
HLA-DRB1*14 alleles comprise the group of HLA SE
alleles, which are associated with RA [56]. The reactivity
to FN-Cit1035,1036 was compared with the HLA-DRB1
alleles of the 278 early arthritis patients. The results
showed that the presence of HLA SE alleles is associated
with the production of anti-citrullinated fibronectin
antibodies, because patients carrying HLA SE alleles are
more than two times more likely to have autoantibodies
against citrullinated fibronectin (OR = 2.11; Table 3 and
Additional file 1: Table S1). When addressing individual
HLA-DRB1 alleles, only HLA-DRB1*04 (OR = 1.5), and
HLA-DRB1*10 (OR = 1.57) showed a weak to moderate
association with the presence of anti-FN-Cit1035,1036
antibodies. Although a more pronounced association
was observed with HLA-DRB1*08 (OR = 2.45) and HLA-
DRB1*16 (OR = 2.43), these data should be interpreted
with care because the carriage of these alleles is rare
and the data are based on only a low number of
patients. Interestingly, a negative association was
observed between the presence of anti-citrullinated
fibronectin antibodies and two additional HLA-DRB1
alleles, HLA-DRB1*09 and HLA-DRB1*11 (OR = 0.19
Figure 3 Recognition of citrullinated fibronectin peptides by diseased and healthy control sera. The peptides FN-Arg/Cit1035,1036 and FN-
Arg/Cit2356 were used to study the specificity of the anti-FN antibodies. A. Reactivity of RA sera and control sera to FN-Cit1035,1036. B. Reactivity of
RA sera and control sera to FN-Cit2356. C. Reactivity of RA sera and control sera to FN-Arg1035,1036. D. Reactivity of RA sera and control sera to FN-
Arg2356. RA (n = 75); pSS = primary Sjőgren’s syndrome (n = 31); MS = multiple sclerosis (n = 31); SLE = systemic lupus erythematosus (n = 31);
T1D = type 1 diabetes (n = 32); TB = tuberculosis (n = 29); NS = normal human sera (n = 32). Broken lines indicate cutoff values (mean + 2*SD
of NS data); OD450 = optical density at 450 nm.
van Beers et al. Arthritis Research & Therapy 2012, 14:R35
http://arthritis-research.com/content/14/1/R35
Page 7 of 16
and OR = 0.41, respectively) (Additional file 1: Table
S1).
In addition, the potential relationship of smoking with
the production of anti-citrullinated fibronectin antibo-
dies was assessed and a weak association was found (OR
= 1.42). We did not observe significant associations
between the presence of anti-citrullinated fibronectin
antibodies and clinical parameters, such as VAS score,
HAQ score, Ritchie index or swollen joint count at
baseline (data not shown).
Discussion
The analysis of citrullinated proteins in the synovial
fluids of two rheumatoid arthritis patients revealed
fibronectin as one of the multiply citrullinated proteins
in both patients. Two of the four synthetic peptides that
were derived from the citrullinated regions of FN
appeared to be reactive with ACPA in the sera of RA
patients. The most frequently targeted FN peptide, FN-
Cit1035,1036, which contains two adjacent citrullines, was
recognized by 50% of established and 45% of early
ACPA-positive RA patients. Like ACPA in general, anti-
FN-Cit1035,1036 antibodies appeared to be associated with
HLA-DRB1 shared epitope alleles.
FN is a complex protein, characterized by the pre-
sence of three types of repeats in its polypeptide
sequence, for which many isoforms resulting from alter-
native splicing events have been described (Figure 1C).
The UniProtKB database provides details of 15 isoforms,
with isoform 1 (FN1 in Figure 1C) as the canonical
sequence. The overall sequence coverage of the mass
spectrometry datasets relative to FN1 comprises 53%
Figure 4 Anti-citrullinated fibronectin peptide antibodies in relation to anti-CCP2 positivity. The peptide set FN-Arg/Cit1035,1036 was used
to study the presence of anti-FN antibodies in anti-CCP2 positive (n = 138) and anti-CCP2 negative (n = 28) RA sera. The broken line indicates
the cut-off value (mean + 2*SD of data obtained with normal human control sera); OD450 = optical density at 450 nm.
Table 2 Sensitivity and specificity of anti-citrullinated fibronectin antibodies.
Patient group n anti-FN-Cit1035,1036 positive sensitivity (%) specificity (%)
established RAa 82 41 50.0
early RAa 278 124 44.6
Controls 186 3 1.6 98.4
non-RA 154 3 1.9 98.1
Healthy 32 0 0 100
a Based upon CCP2-positive sera
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and 28% for both synovial fluid samples, respectively. It
is likely that multiple FN isoforms are expressed in the
inflamed synovia of RA patients and our data do not
allow drawing conclusions on their relative abundance.
Three regions of FN are especially prone to alternative
splicing; at the protein level these are termed extra
domain A (EDA), extra domain B (EDB) and type III
connecting segment (IIICS). Although peptides were
found that match part of the IIICS sequence, no pep-
tides were detected for EDA and EDB. Moreover, a few
peptides provide evidence for the absence of EDA and
EDB in the isoform(s) they originate from, because their
sequences covered the regions immediately N- and C-
terminal from EDA or from EDB. The EDA domain,
also designated EIIIA, has been implicated in inflamma-
tion, because it was shown to be involved in Toll-like
receptor (TLR) 4 activation [57]. Although our data do
not support the presence of EDA-containing FN iso-
forms in the synovial fluid of RA patients, it has been
demonstrated previously that EDA-containing FN is
produced in the RA synovium and is expressed abun-
dantly in RA SF [58,59]. Moreover, recently Lefebvre
and colleagues showed that EDA-containing FN stimu-
lated leukotriene synthesis and neutrophil recruitment
via TLR activation in a mouse model [60]. Although we
could not detect any peptides in the EDA region, our
data do not exclude the presence of EDA-containing FN
isoforms in RA synovial fluid samples, because we have
only analyzed a limited number of patients or because
of technical limitations, such as ionization efficiencies.
The interpretation of the data is further complicated
by the fact that FN-derived peptides were found in
material from many gel slices, which indicates a high
heterogeneity of FN polypeptide lengths. It is likely that
this is at least in part due to the presence of proteolytic
enzymes in the synovial fluid from inflamed joints,
which cleave the FN polypeptides in different fragments.
It is known that during inflammation proteases are
active in synovial fluid and can contribute to RA patho-
genesis [61,62]. Indeed, the fragmentation of FN in
inflammatory SF [63], as well as in cartilage of RA and
osteoarthritis patients [64] has been reported previously.
Our analyses identified five citrullinated residues in
FN from RA patient SF. Except for two adjacent citrul-
lines, these residues are found in distant regions of the
FN polypeptide chain. Our data do not provide informa-
tion on the extent to which these residues are citrulli-
nated in RA SF and it is likely that differences between
patients exist. This is substantiated by the observation
that in material from RA2 for the region containing the
two adjacent citrullines only one of these two residues
(1035) was found to be citrullinated, whereas both were
citrullinated in RA1. Two other studies have previously
reported the presence of citrullinated FN in SF and
synovial tissue of RA patients [41,43]. However, these
studies did not reveal the positions of the citrullinated
residues. Our data do not exclude the possibility that
FN is also citrullinated at other positions in RA SF,
because material from only two patients was analyzed in
detail and the sequence coverage was not more than
Figure 5 Anti-citrullinated fibronectin peptide antibodies in early arthritis patient sera. A. Sera from anti-CCP2-negative (n = 23) and anti-
CCP2-positive (n = 24) early arthritis patients were analyzed in the FN-Cit1035,1036 ELISA. B. Sera from anti-CCP2-positive early arthritis patients (n
= 278) were analyzed in the FN-Cit1035,1036 ELISA. The broken line indicates the cut-off value (mean + 2*SD of data obtained with normal human
control sera); OD450 = optical density at 450 nm.
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Figure 6 Anti-FN-Cit1035,1036 antibodies are predominantly of the IgG isotype. Sera from a subset of anti-FN-Cit1035,1036-positive early
arthritis patients (n = 23) taken at baseline (t = 0) and after a median follow-up of seven years later (t = 7) were analyzed for different anti-FN-
Cit1035,1036 antibody isotypes in ELISA. A. IgG isotype reactivity at t = 0. B. IgG isotype reactivity at t = 7. C. IgM isotype reactivity at t = 0. D. IgM
isotype reactivity at t = 7. E. IgA isotype reactivity at t = 0. F. IgA isotype reactivity at t = 7. G. Anti-FN-Cit1035,1036 IgG reactivity at t = 0 and t =
7. The broken lines indicate the cut-off values determined by normal human control sera.
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53%. Moreover, if citrullination enhances FN’s suscept-
ibility to proteolytic cleavage, citrullinated peptides may
have escaped detection as a result of cleavages by endo-
genous proteases that cleave the polypeptide close to
the citrullinated residue.
A synthetic peptide approach to investigate the recog-
nition of citrullinated epitopes of FN by RA autoantibo-
dies revealed that the major autoepitope is located in
the region containing the two adjacent citrullines
(amino acids 1035 and 1036). Only one of the other
three citrullinated peptides was recognized by some RA
sera. The fact that RA sera were only reactive with two
of these peptides is consistent with the results of other
studies showing that the amino acids flanking the citrul-
line residue contribute to the formation of auto-epitopes
[1]. Several studies [24,34,65] with synthetic citrullinated
peptides (derived from vimentin, fibrinogen and a-eno-
lase) showed that not all peptides containing citrulli-
nated residues are recognized by patient sera, indicating
that not only the citrulline is important, but also the
amino acids surrounding the citrullinated residue. How-
ever, it should be noted that the use of synthetic pep-
tides in general does not allow the identification of
reactivities with conformational and/or discontinuous
epitopes. Therefore, our data do not exclude the possibi-
lity that the citrullinated residues identified are part of
conformational epitopes and that autoantibodies to
these epitopes may be present in RA patient sera.
Although autoantibodies to FN have been detected in
RA as well as SLE patients before [66,67], our data are
the first to describe antibodies that target FN in a citrul-
line-dependent manner. The autoantibodies that can be
detected with the FN-Cit1035,1036 peptide represent a
subset of ACPA, which is substantiated by the lack of
correlation between the levels of reactivity with CCP2
and with FN-Cit1035,1036 (Additional file 1: Figure S3). In
total, 50% of the (anti-CCP2-positive) established RA
patients showed reactivity to FN-Cit1035,1036, compared
to two percent of the controls (non-RA and healthy
individuals; Table 2).
The possibility existed that the anti-FN-Cit1035,1036
subset of ACPA overlapped with another subset that has
been identified previously, as a result of epitope similari-
ties. ACPA fine-specificity data were available for most
of the EAC patient sera. The reactivity of these sera
with FN-Cit1035,1036 was compared with their reactivity
with two citrullinated peptides derived from vimentin
(vimentin-1-16: STCitSVSSSSYCitCitMFGG; vimentin-
59-74: VYATCitSSAVCitLCitSSVP), two peptides
derived from fibrinogen (a-fibrinogen-27-43:
FLAEGGGVCitGPRVVERH; b-fibrinogen-36-52:
NEEGFFSACitGHRPLDKK) and one peptide derived
from a-enolase (a-enolase-5-20: KIHACitEIFDS-
CitGNPTV) [39]. These analyses showed that most of
the EAC sera recognized multiple citrullinated epitopes
(Figure 7A). A large overlap of anti-FN-Cit1035,1036 with
reactivities to any of the other peptides was observed, as
might be expected from previous data [26,68]. However,
some sera appeared to react exclusively with FN-
Cit1035,1036 and not with the other citrullinated epitopes
(Figure 7B). These data are underscoring the large het-
erogeneity of the ACPA response in RA and indicate
that the anti-FN-Cit1035,1036 antibodies are one of the
most abundant ACPA subclasses that can be detected
with synthetic peptides derived from citrullinated syno-
vial proteins. Taken together, these data indicate that
this citrullinated FN peptide may be used to investigate
the fine-specificity of ACPA in more detail and may be
complementary to other citrullinated molecules in
ACPA profiling.
The anti-FN-Cit1035,1036 antibodies present in early
arthritis patients appeared to be predominantly of the
IgG isotype. Only a small percentage of sera was found
to contain IgM or IgA type anti-FN-Cit1035,1036 antibo-
dies. After a median follow-up of seven years, the IgG
type reactivities were hardly changed, whereas the pre-
valence of IgM reactivity against FN-Cit1035,1036 was
decreased, and that of IgA was somewhat increased.
Similar observations have been reported for samples
from undifferentiated arthritis patients (who developed
RA) taken either at baseline or after one year follow-up
[36]. It remains an open question whether the anti-
citrullinated FN antibodies play a pathophysiological
role. FN-containing immune complexes are likely to be
formed in the inflamed joints of RA patients and this
may occur already early during disease development.
Further studies will be required to elucidate whether
citrullinated FN is involved in the inflammatory process.
Table 3 Association of anti-citrullinated fibronectin antibodies with smoking and SE alleles
Anti-cit FN neg. (%)d Anti-cit FN pos. (%)d OR (95% CI)
Smokinga - 63 (46.7) 40 (38.1) 1.42 (0.85 to 2.39)
+ 72 (53.3) 65 (61.9)
HLA SE allelesb - 39 (26.5) 57 (14.6) 2.11 (1.13 to 3.92)
+ 108 (73.5) 213 (85.4)
a Based upon information obtained from 240 RA patients. b Based upon information obtained from 270 RA patients. 95% CI, 95% confidence interval; OR, odds
ratio
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Figure 7 Anti-FN-Cit1035,1036 in relation to other ACPA. The reactivity of EAC sera (n = 228) with FN-Cit1035,1036 was compared with the
presence of antibodies to other citrullinated peptides, which are derived from vimentin (1 to 16: STCitSVSSSSYCitCitMFGG and 59 to 74:
VYATCitSSAVCitLCitSSVP), fibrinogen (a-fibrinogen 27 to 43: FLAEGGGVCitGPRVVERH; b-fibrinogen 36 to 52: NEEGFFSACitGHRPLDKK) and a-
enolase (5 to 20: KIHACitEIFDSCitGNPTV) [39]. A. Fraction of patients recognizing 0 to 6 citrullinated peptides. B. Heat map showing the presence
of antibodies to the citrullinated peptides obtained by an unsupervised cluster analysis. Red and green mark positive and negative sera,
respectively. Missing values are depicted in grey.
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The presence of anti-citrullinated FN antibodies in the
early arthritis patients was associated with HLA SE
alleles (OR = 2.11). Of the individual SE alleles, only
HLA-DRB1*04 and HLA-DRB1*10 showed a weak asso-
ciation with the presence of anti-citrullinated FN pep-
tide antibodies (Additional file 1: Table S1). Previously,
Snir and co-workers demonstrated that antibodies
against multiple citrullinated antigens (for example,
vimentin, fibrinogen, a-enolase and the C1-epitope of
type II collagen) were associated with SE alleles, particu-
larly with HLA-DRB1*04 [26,69]. Our data show a nega-
tive association of HLA-DRB1*09 and HLA-DRB1*11
with the presence of anti-citrullinated FN peptide anti-
bodies (OR = 0.19 and OR = 0.41, respectively). This
may be in agreement with the previously reported asso-
ciation of the HLA-DRB1*0901 haplotype with reduced
levels of anti-CCP antibodies [70]. Paradoxically, HLA-
DRB1*09 has been reported previously to be associated
with RA in Asian as well as Caucasian individuals
[71,72]. In addition, it should be noted that, because
ACPA-positive RA patients comprise a strong preva-
lence for SE-allelles, other HLA-DRB1 alleles are less
frequently present than SE-alleles and, therefore, might
seem to be protective. As a consequence, the negative
association observed with HLA-DRB1*09 and HLA-
DRB1*11 might also be the result of skewing [73].
We did not detect a significant association between
clinical phenotype and the presence of anti-citrullinated
fibronectin in ACPA-positive RA patients. Recently,
Scherer and colleagues also observed no effect on radio-
graphic joint damage in patients that were positive for
several citrullinated epitopes [37]. Nevertheless, a weak
correlation between the presence of autoantibodies
against citrullinated FN and smoking, a risk factor for
ACPA generation, particularly in individuals that carry
the SE alleles [16,17], was observed.
Conclusion
Five citrullinated residues were identified in fibronectin
isolated from the inflamed joints of RA patients. An epi-
tope containing two adjacent citrullines at positions cor-
responding to residues 1035 and 1036 appeared to be
most frequently recognized by RA sera. Our data not
only show that antibodies against citrullinated FN are
present in RA patients, but also demonstrate that the
anti-FN antibodies represent a subgroup of anti-CCP2
antibodies and that they can already be detected very
early in the disease. Moreover, anti-FN-Cit1035,1036 anti-
bodies are associated primarily with HLA SE alleles.
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